As of 2024-12-13, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 792.10 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 10.0x | 8.6x |
| Forward P/E multiples | 13.1x - 19.1x | 16.2x |
| Fair Price | (19.08) - (15.24) | (18.30) |
| Upside | -717.5% - -593.2% | -692.1% |
| Date | EV/EBITDA |
| 2024-12-12 | -4.83 |
| 2024-12-11 | -4.79 |
| 2024-12-10 | -4.78 |
| 2024-12-09 | -4.79 |
| 2024-12-06 | -5.42 |
| 2024-12-05 | -5.52 |
| 2024-12-04 | -5.71 |
| 2024-12-03 | -5.50 |
| 2024-12-02 | -5.35 |
| 2024-11-29 | -5.25 |
| 2024-11-27 | -5.39 |
| 2024-11-26 | -5.58 |
| 2024-11-25 | -5.41 |
| 2024-11-22 | -5.35 |
| 2024-11-21 | -5.44 |
| 2024-11-20 | -5.41 |
| 2024-11-19 | -5.37 |
| 2024-11-18 | -5.56 |
| 2024-11-15 | -5.71 |
| 2024-11-14 | -5.82 |
| 2024-11-13 | -5.76 |
| 2024-11-12 | -5.67 |
| 2024-11-11 | -5.12 |
| 2024-11-08 | -5.33 |
| 2024-11-07 | -7.00 |
| 2024-11-06 | -7.03 |
| 2024-11-05 | -7.05 |
| 2024-11-04 | -7.03 |
| 2024-11-01 | -7.02 |
| 2024-10-31 | -7.10 |
| 2024-10-30 | -7.12 |
| 2024-10-29 | -7.11 |
| 2024-10-28 | -7.10 |
| 2024-10-25 | -6.13 |
| 2024-10-24 | -6.62 |
| 2024-10-23 | -6.61 |
| 2024-10-22 | -6.61 |
| 2024-10-21 | -6.60 |
| 2024-10-18 | -6.61 |
| 2024-10-17 | -6.52 |
| 2024-10-16 | -6.60 |
| 2024-10-15 | -6.54 |
| 2024-10-14 | -6.49 |
| 2024-10-11 | -6.60 |
| 2024-10-10 | -6.58 |
| 2024-10-09 | -6.57 |
| 2024-10-08 | -6.55 |
| 2024-10-07 | -6.64 |
| 2024-10-04 | -6.55 |
| 2024-10-03 | -6.58 |